When LCK activates T cells, the secretion of IL-2 increases, which, in turn, activates CD8+ T cells within the tumour to increase the ability of ICIs to inhibit tumours and reduce drug toxicity [65,66]. The gene discussed is CD8A; the disease is neoplasm.